Literature DB >> 29885360

Determinants of human glucokinase activation and implications for small molecule allosteric control.

Quinn Li1, Lokesh Gakhar2, M Ashley Spies3.   

Abstract

Glucokinase (GK) is an enzyme that catalyzes the ATP-dependent phosphorylation of glucose to form glucose-6-phosphate, and it is a tightly regulated checkpoint in glucose homeostasis. GK is known to undergo substantial conformational changes upon glucose binding. The monomeric enzyme possesses a highly exotic kinetic activity profile with an unusual sigmoidal dependence on glucose concentration. In this interdisciplinary study, which draws on small angle X-ray scattering (SAXS) integrated with 250 ns of atomistic molecular dynamics (MD) simulations and experimental glucose binding thermodynamics, we reveal that the critical regulation of this glucose sensor is due to a solvent controlled "switch". We demonstrate that the "solvent switch" is driven by specific protein structural dynamics, which leads to an enzyme structure that has a much more favorable solvation energy than most of the protein ensemble. These findings uncover the physical workings of an agile and flexible protein scaffold, which derives its long-range allosteric control through specific regions with favorable solvation energy. The physiological framework presented herein provides insights that have direct implications for the design of small molecule GK activators as anti-diabetes therapeutics as well as for understanding how proteins can be designed to have built-in regulatory functions via solvation energy dynamics.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allostery; Diabetes; Glucokinase; Protein-solvent interactions; SAXS/MD

Mesh:

Substances:

Year:  2018        PMID: 29885360      PMCID: PMC6051901          DOI: 10.1016/j.bbagen.2018.06.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  36 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Probing protein hydration and conformational states in solution.

Authors:  C Reid; R P Rand
Journal:  Biophys J       Date:  1997-03       Impact factor: 4.033

3.  A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations.

Authors:  Yong Duan; Chun Wu; Shibasish Chowdhury; Mathew C Lee; Guoming Xiong; Wei Zhang; Rong Yang; Piotr Cieplak; Ray Luo; Taisung Lee; James Caldwell; Junmei Wang; Peter Kollman
Journal:  J Comput Chem       Date:  2003-12       Impact factor: 3.376

4.  Making optimal use of empirical energy functions: force-field parameterization in crystal space.

Authors:  Elmar Krieger; Tom Darden; Sander B Nabuurs; Alexei Finkelstein; Gert Vriend
Journal:  Proteins       Date:  2004-12-01

5.  Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.

Authors:  Ramakanth Sarabu; Fred T Bizzarro; Wendy L Corbett; Mark T Dvorozniak; Wanping Geng; Joseph F Grippo; Nancy-Ellen Haynes; Stanley Hutchings; Lisa Garofalo; Kevin R Guertin; Darryl W Hilliard; Marek Kabat; Robert F Kester; Wang Ka; Zhenmin Liang; Paige E Mahaney; Linda Marcus; Franz M Matschinsky; David Moore; Jagdish Racha; Roumen Radinov; Yi Ren; Lida Qi; Michael Pignatello; Cheryl L Spence; Thomas Steele; John Tengi; Joseph Grimsby
Journal:  J Med Chem       Date:  2012-08-01       Impact factor: 7.446

6.  Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.

Authors:  E A Davis; A Cuesta-Muñoz; M Raoul; C Buettger; I Sweet; M Moates; M A Magnuson; F M Matschinsky
Journal:  Diabetologia       Date:  1999-10       Impact factor: 10.122

7.  Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations.

Authors:  Vladi V Heredia; Thomas J Carlson; Erin Garcia; Shaoxian Sun
Journal:  J Biol Chem       Date:  2006-11-02       Impact factor: 5.157

8.  Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.

Authors:  Henrik B T Christesen; Nicholas D Tribble; Anders Molven; Juveria Siddiqui; Tone Sandal; Klaus Brusgaard; Sian Ellard; Pål R Njølstad; Jan Alm; Bendt Brock Jacobsen; Khalid Hussain; Anna L Gloyn
Journal:  Eur J Endocrinol       Date:  2008-05-01       Impact factor: 6.664

Review 9.  Present status of clinical deployment of glucokinase activators.

Authors:  Akinobu Nakamura; Yasuo Terauchi
Journal:  J Diabetes Investig       Date:  2014-11-10       Impact factor: 4.232

10.  Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction.

Authors:  Shyamal Subramanyam; William T Jones; Maria Spies; M Ashley Spies
Journal:  Nucleic Acids Res       Date:  2013-08-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.